---
title: "688075.SH (688075.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688075.SH/news.md"
symbol: "688075.SH"
name: "688075.SH"
parent: "https://longbridge.com/en/quote/688075.SH.md"
datetime: "2026-03-08T08:47:05.750Z"
locales:
  - [en](https://longbridge.com/en/quote/688075.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688075.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688075.SH/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/688075.SH/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/688075.SH/news.md)


# 688075.SH (688075.SH) — Related News

### [After collaborating with Fubon Life Insurance, Pusen is once again partnering with Fubon Property Insurance this year to promote cancer insurance combined with health check services](https://longbridge.com/en/news/277919018.md)
*2026-03-05T10:25:28.000Z*
> Progenity (4117) has partnered with Fubon Insurance to launch a cancer insurance combined with health screening services

### [Assure Tech: Shareholder Ma Huaxiang has reduced his holdings by 0.94%](https://longbridge.com/en/news/277585753.md)
*2026-03-03T08:19:14.000Z*
> Assure Tech announced that the company's shareholder Ma Huaxiang reduced his holdings by 1.2 million shares through cent

### [Assure Tech: Net profit in 2025 is expected to decline by 61.84% year-on-year](https://longbridge.com/en/news/277167244.md)
*2026-02-27T08:43:19.000Z*
> Assure Tech announced that the company achieved operating revenue of 453.5751 million yuan in 2025, a decrease of 16.11%

### [YaoTang Biotech's YOLT-203 has received advanced therapy designation from the U.S. FDA for regenerative medicine](https://longbridge.com/en/news/274475936.md)
*2026-02-02T07:12:37.000Z*
> On February 2nd, YaoTang Biotech announced that its investigational in vivo gene editing therapy YOLT-203 has received R

### [Assure Tech issued a profit warning, expecting the annual net profit attributable to shareholders in 2025 to decrease by 55.80% to 63.08% year-on-year](https://longbridge.com/en/news/274319854.md)
*2026-01-30T13:49:03.000Z*
> Assure Tech released its 2025 annual performance forecast, expecting a net profit attributable to the parent company's o

### [Focusing on the development of new cancer drugs, Biling Bio has completed over 200 million yuan in Series B financing](https://longbridge.com/en/news/273936412.md)
*2026-01-28T05:10:25.000Z*
> Shanghai Biling Biotechnology Co., Ltd. has completed over 200 million yuan in Series B financing, led jointly by Hongch

### [Assure Tech: Shareholder Ma Huaxiang, holding over 5% of shares, reduced his stake in the company, reaching a 1% threshold](https://longbridge.com/en/news/273337517.md)
*2026-01-22T07:50:00.000Z*
> Assure Tech announced that shareholder Ma Huaxiang will reduce his holdings by 804,519 shares from January 6 to 21, 2026